Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Slower Progression Rates in Lower Limb-Onset ALS.

Journal of clinical medicine·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026
Same author

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2026
Same author

The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United States.

Neurology research international·2026
Same author

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

Muscle & nerve·2026

相关实验视频

Updated: Jun 9, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

20.6K

用IPL344激活阿克特治疗肌缩侧面硬化症:首次在人类中进行开放性研究

Marc Gotkine1, David A Schoenfeld2, Ilana Cohen3

  • 1Neuromuscular Unit, Department of Neurology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Muscle & nerve
|March 19, 2025
PubMed
概括

这项研究发现,Akt通路激活剂IPL344在肌缩性侧面硬化症 (ALS) 患者中是安全的,并且耐受性良好. 初步结果表明IPL344可能会减缓ALS的进展并改善存活率,因此需要进一步调查.

关键词:
标签: 活动 活动 活动在IPL344中,使用IPL344.骨髓缩侧面硬化症 (ALS) 是一种临床试验临床试验临床试验临床试验临床试验

更多相关视频

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.0K
Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons
11:52

Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons

Published on: August 26, 2021

2.2K

相关实验视频

Last Updated: Jun 9, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

20.6K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.0K
Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons
11:52

Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons

Published on: August 26, 2021

2.2K

科学领域:

  • 神经科学是一个神经科学.
  • 临床试验 临床试验
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 在Akt细胞内信号传导途径的功能障碍与肌缩性侧面硬化症 (ALS) 有关.
  • 准Akt路径为ALS干预提供了一个新的治疗策略.

研究的目的:

  • 为了评估IPL344的安全性,耐受性和初步疗效,Akt通路激活剂,在ALS患者的首次人体研究中.

主要方法:

  • 9名患有ALS的参与者每天接受开放式IPL344治疗,长达36个月.
  • 通过不良事件报告监测安全性;评估了血神经纤维光链 (NfL) 水平和临床结果 (ALSFRS-R).
  • 结果与历史对照数据进行了比较.

主要成果:

  • IPL344在一般情况下是安全的,耐受性很好,可控的不良事件.
  • 与历史对照相比,观察到ALSFRS-R下降速度较慢48% (p=0.028),调整后的分析显示进展速度较慢64%.
  • 血NfL度降低了27%,IPL344组的中位生存时间明显更长 (43.4个月与19.1个月相比).

结论:

  • 初步发现表明IPL344是安全的,耐受性良好,并可能有效地减缓ALS的进展.
  • 观察到的临床结果和生存率的改善需要在更大规模的安慰剂对照试验中进一步调查.